MHUA - Meihua Internationa... Stock Analysis | Stock Taper
Logo
Meihua International Medical Technologies Co., Ltd.

MHUA

Meihua International Medical Technologies Co., Ltd. NASDAQ
$9.66 -0.51% (-0.05)

Market Cap $3.06 M
52w High $67.70
52w Low $2.65
P/E 0.31
Volume 3.05K
Outstanding Shares 316.73K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $37.98M $9.37M $3.15M 8.28% $9.86 $3.51M
Q4-2024 $51.57M $9.61M $6.13M 11.88% $21 $9.4M
Q2-2024 $45.34M $9.24M $4.72M 10.4% $17 $6.18M
Q4-2023 $48.91M $10.41M $4.56M 9.33% $19.06 $5.75M
Q2-2023 $48.19M $8M $7.06M 14.65% $30 $9.53M

What's going well?

The company is still profitable despite the sharp drop in sales. Other income provided a helpful boost, and there are no major one-time charges distorting results.

What's concerning?

Revenue fell sharply, profits were cut in half, and margins are getting squeezed. Costs are not falling as fast as sales, and share dilution is hurting per-share results.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $15.55M $190.58M $25.64M $164.95M
Q4-2024 $15.96M $186.24M $27.26M $158.98M
Q2-2024 $18.49M $179.16M $29.59M $149.57M
Q4-2023 $16.93M $171.92M $25.08M $146.33M
Q2-2023 $17.86M $162.61M $23.22M $138.89M

What's financially strong about this company?

MHUA has a huge cushion of equity, very little debt, and most assets are cash or receivables. Liquidity is excellent, and the company has a long track record of profits.

What are the financial risks or weaknesses?

Debt rose slightly this quarter, and cash dipped a bit, but these are minor. Receivables are a large portion of assets, so slow-paying customers could be a risk if the economy turns.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $3.15M $-19.8M $12.18M $6.62M $-386.49K $-9.91M
Q4-2024 $6.13M $13.62M $-15M $79.43K $0 $13.5M
Q2-2024 $4.72M $1.02M $-5.42M $6.13M $781.88K $1.01M
Q4-2023 $4.56M $7.7M $-8.59M $-15.55K $-467.17K $7.52M
Q2-2023 $7.06M $-5.42M $-3.87M $721.68K $-8.88M $-10.01M

What's strong about this company's cash flow?

The company still has $16.9 million in cash, and capital spending is low, so it can adjust quickly if needed.

What are the cash flow concerns?

Cash flow swung from positive to negative, working capital is draining cash, and the company now needs to borrow just to keep operating. If this continues, cash could run out soon.

5-Year Trend Analysis

A comprehensive look at Meihua International Medical Technologies Co., Ltd.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

The company combines a broad, established product portfolio and long operating history with a notably strong balance sheet: low debt, ample liquidity, and growing equity. It remains consistently profitable despite recent margin pressure and has recently delivered a marked improvement in operating and free cash flow. Certifications, regulatory approvals, and deep customer relationships, plus active R&D and digital initiatives like the Speed Fox platform and the Hainan import hub, provide a platform for potential future growth.

! Risks

Key concerns center on declining profitability, shrinking margins, and falling earnings per share against a backdrop of largely flat revenue. The business has a history of volatile and sometimes weak cash generation, operates in a highly competitive and price-sensitive segment, and faces ongoing regulatory and market-access risks. Volatility in intangibles and the need to address stock-market listing issues, including a reverse split and prior delisting notices, add governance and capital-market uncertainty.

Outlook

The overall picture is of a company with solid financial foundations but under operational and competitive pressure. Its strong balance sheet and recent cash flow recovery give it time and flexibility to adjust strategy, while current innovation and expansion initiatives offer potential upside if they translate into higher-margin growth. At the same time, the outlook is tempered by the need to stabilize margins, demonstrate consistent cash generation, and successfully execute new projects in a challenging, commoditized market environment.